WHO: ‘Cobra’ vaccine is in critical condition

NEW YORK (AP) The World Health Organization has warned about an Ebola vaccine being in critical and critical condition in the Philippines after it was withdrawn from a clinical trial for the virus in the Pacific island nation.

A vaccine that has been licensed in the U.S. for use against Ebola has not been tested in the islands of Mindanao and Samar.

The vaccine is for use in two countries in West Africa.

The WHO said Friday that the Philippine vaccine is now being tested in a clinical study in New York and New Jersey, and will be taken to Europe.

It said that it was not aware of the reason for the withdrawal of the vaccine from the Philippines.

The Philippines is home to an estimated 3 million people and is the world’s third-largest producer of vaccine.

A U.N. panel on Thursday ordered a halt to the U,S.

production of a new Ebola vaccine, saying it has not yet received data to back it up.

The panel also ordered a freeze on any new vaccine that could contain any material that could be used to produce the new vaccine.

The United States, Canada and China have also all pledged to halt production of their own vaccines.

The U.K. government is also reviewing the U.,S.

vaccine.

The vaccine is based on the same vaccine used in Liberia, which was cleared for use by the WHO’s global advisory panel last month.

The World Health Organisation (WHO) said Friday it is withdrawing the Philippines vaccine from a trial in New Jersey because it does not meet WHO’s standards of safety and efficacy.

It is also withdrawing the vaccine, which is licensed in U.R. Philippines, from a similar trial in Australia because it did not meet its standards of clinical trial quality.

The new vaccine was approved in the United States for use as a drug in Sierra Leone in 2016 and in Sierra Maestra in the Dominican Republic in 2019.

The trial, which lasted from October through December of last year, was conducted in a private hospital in the country.